Valentina Guarneri
Overview
Explore the profile of Valentina Guarneri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
231
Citations
4507
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Buja A, Rugge M, Bortolami A, Zorzi M, Rea F, Zanovello A, et al.
Cancers (Basel)
. 2025 Feb;
17(4).
PMID: 40002243
Introduction: This retrospective follow-up study evaluates patient outcomes and treatment costs in two cohorts of incident NSCLC patients recorded in the population-based cancer registry of the Veneto Region in 2017...
2.
Griguolo G, Bottosso M, Crema A, Giarratano T, Miglietta F, Bonomi G, et al.
Eur J Cancer
. 2025 Feb;
219:115321.
PMID: 39987798
Background: Interest in metastatic solid tumors patients achieving exceptionally durable responses to systemic treatment is progressively increasing; however, available evidence still remains limited. This study characterizes patients with metastatic breast...
3.
Bottosso M, Griguolo G, Guiu S, Guarascio M, Bailleux C, Miglietta F, et al.
NPJ Breast Cancer
. 2025 Feb;
11(1):20.
PMID: 39979277
Brain metastases (BMs) are a common complication of advanced breast cancer (BC), and their management has significantly evolved. We evaluated the clinical impact of these changes dividing patients diagnosed with...
4.
Dieci M, Bisagni G, Bartolini S, Schirone A, Cavanna L, Musolino A, et al.
JAMA Oncol
. 2025 Feb;
PMID: 39946142
Importance: For patients with early ERBB2 (formerly HER2)-positive breast cancer, there is a need to identify biomarkers to guide treatment de-escalation. Objective: To evaluate the association of tumor-infiltrating lymphocytes (TILs)...
5.
Mastrantoni L, Garufi G, Giordano G, Maliziola N, Di Monte E, Arcuri G, et al.
NPJ Breast Cancer
. 2025 Feb;
11(1):11.
PMID: 39910103
Hormone receptor-positive/HER2-negative breast cancer (BC) is the most common subtype of BC and typically occurs as an early, operable disease. In patients receiving neoadjuvant chemotherapy (NACT), pathological complete response (pCR)...
6.
Loi S, Salgado R, Curigliano G, Romero Diaz R, Delaloge S, Rojas Garcia C, et al.
Nat Med
. 2025 Jan;
31(2):433-441.
PMID: 39838118
Patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) primary breast cancer (BC) have low pathological complete response (pCR) rates with neoadjuvant chemotherapy. A subset of ER+/HER2-...
7.
Geyer Jr C, Untch M, Huang C, Mano M, Mamounas E, Wolmark N, et al.
N Engl J Med
. 2025 Jan;
392(3):249-257.
PMID: 39813643
Background: Patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer with residual invasive disease after neoadjuvant systemic therapy have a high risk of recurrence and death. The...
8.
Harbeck N, Ciruelos E, Jerusalem G, Muller V, Niikura N, Viale G, et al.
Nat Med
. 2024 Dec;
30(12):3780.
PMID: 39653780
No abstract available.
9.
Boscolo Bragadin A, Del Bianco P, Zulato E, Attili I, Pavan A, Carlet J, et al.
NPJ Precis Oncol
. 2024 Oct;
8(1):234.
PMID: 39420036
High heterogeneity in clinical benefit characterizes the use of immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC). We prospectively enrolled 113 advanced NSCLC patients treated with ICIs and...
10.
Slomovitz B, Cibula D, Lv W, Ortac F, Hietanen S, Backes F, et al.
J Clin Oncol
. 2024 Oct;
43(3):251-259.
PMID: 39411812
Mismatch repair-deficient (dMMR) endometrial cancer (EC) is an inflamed phenotype with poor outcomes when meeting high-risk criteria and limited treatment options in the adjuvant setting. We report protocol-prespecified subgroup analysis...